Targeting annexin-A1 can halt cancer cell growth, study finds

A new study published in Oncogene highlights the effectiveness of MDX-124, the first therapeutic drug to target annexin-A1, a protein that is overexpressed in several cancer types and promotes tumor progression.

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart